Is Neon Therapeutics, Inc. (NTGN)’s Fuel For Real? The Stock Just Increased Again

The stock of Neon Therapeutics, Inc. (NASDAQ:NTGN) is a huge mover today! The stock increased 6.84% or $0.18 during the last trading session, reaching $2.81. About 200,410 shares traded or 7.52% up from the average. Neon Therapeutics, Inc. (NASDAQ:NTGN) has declined 74.73% since August 15, 2018 and is downtrending. It has underperformed by 74.73% the S&P500.
The move comes after 9 months positive chart setup for the $79.75 million company. It was reported on Aug, 15 by Barchart.com. We have $2.92 PT which if reached, will make NASDAQ:NTGN worth $3.19M more.

More notable recent Neon Therapeutics, Inc. (NASDAQ:NTGN) news were published by: Globenewswire.com which released: “Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting – GlobeNewswire” on February 27, 2019, also Seekingalpha.com with their article: “Pieris Pharmaceuticals and Pluristem Therapeutics among healthcare gainers; Lexicon Pharmaceuticals leads the losers – Seeking Alpha” published on July 29, 2019, Globenewswire.com published: “Neon Therapeutics Reports Second Quarter 2019 Financial Results – GlobeNewswire” on August 06, 2019. More interesting news about Neon Therapeutics, Inc. (NASDAQ:NTGN) were released by: Globenewswire.com and their article: “Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting – GlobeNewswire” published on March 31, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 07/15/2019: CAPR, GLPG, GILD, NTGN, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” with publication date: July 15, 2019.

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. The company has market cap of $79.75 million. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. It currently has negative earnings. Neon Therapeutics, Inc. has a clinical trial collaboration with Natera, Inc. to assess the treatment response to personal cancer vaccine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.